<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00112476</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2011-01382</org_study_id>
    <secondary_id>04-037</secondary_id>
    <secondary_id>FCCC-04037</secondary_id>
    <secondary_id>NCI-5785</secondary_id>
    <secondary_id>CDR0000432955</secondary_id>
    <nct_id>NCT00112476</nct_id>
  </id_info>
  <brief_title>Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors</brief_title>
  <official_title>A Phase I Study of Intravenous CCI-779 in Combination With Bryostatin-1 in Solid Tumors (10038414)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of temsirolimus when given&#xD;
      together with bryostatin 1 in treating patients with unresectable or metastatic solid tumors.&#xD;
      Drugs used in chemotherapy, such as temsirolimus and bryostatin 1, work in different ways to&#xD;
      stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose and recommended phase II dose of temsirolimus when&#xD;
      given together with bryostatin 1 in patients with unresectable or metastatic solid tumors.&#xD;
&#xD;
      II. Determine the dose-limiting toxic effects of this regimen in these patients.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Correlate the extent and duration of inhibition of p70^S6kinase phosphorylation in&#xD;
      peripheral blood mononuclear cells with tumor growth or reduction in these patients.&#xD;
&#xD;
      II. Correlate the phosphorylation total and phospho-AKT and total and phospho ribosomal S6&#xD;
      protein (indicators of mTOR activation) with antitumor effects of this regimen in these&#xD;
      patients.&#xD;
&#xD;
      III. Correlate tumor expression of phospho-ERK1 and -ERK2 with antitumor effects of this&#xD;
      regimen in these patients.&#xD;
&#xD;
      IV. Determine the pharmacokinetics of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of temsirolimus.&#xD;
&#xD;
      Patients receive bryostatin 1 IV over 1 hour on days 1, 8, 15, and 22 and temsirolimus IV&#xD;
      over 30 minutes once on days 8, 15, and 22 during course 1. On subsequent courses patients&#xD;
      receive bryostatin 1 and temsirolimus once on days 1, 8, and 15. Courses repeat every 28 days&#xD;
      in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of temsirolimus until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD of CCI-779 and Bryostatin-1 administered in combination, graded according to NCI Common Toxicity Criteria, Version 3.0</measure>
    <time_frame>28 days</time_frame>
    <description>A dose-limiting toxicity is defined as a toxicity that is &gt;= grade 3 and drug-related.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in sum of RECIST measurements</measure>
    <time_frame>Baseline up to 30 days after completion of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AKT activity, measured by immunohistochemistry (IHC), classified as none, weak, moderate, or strong</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Recurrent Melanoma</condition>
  <condition>Recurrent Renal Cell Cancer</condition>
  <condition>Stage IV Melanoma</condition>
  <condition>Stage IV Renal Cell Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment (bryostatin, temsirolimus)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bryostatin 1 IV over 1 hour on days 1, 8, 15, and 22 and temsirolimus IV over 30 minutes once on days 8, 15, and 22 during course 1. On subsequent courses patients receive bryostatin 1 and temsirolimus once on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bryostatin 1</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (bryostatin, temsirolimus)</arm_group_label>
    <other_name>B705008K112</other_name>
    <other_name>BRYO</other_name>
    <other_name>Bryostatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temsirolimus</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (bryostatin, temsirolimus)</arm_group_label>
    <other_name>CCI-779</other_name>
    <other_name>cell cycle inhibitor 779</other_name>
    <other_name>Torisel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed solid tumor, including melanoma or renal cell carcinoma&#xD;
&#xD;
               -  Metastatic or unresectable disease&#xD;
&#xD;
                    -  Must have evidence of residual, recurrent, or metastatic disease by&#xD;
                       radiography&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques&#xD;
                  (CT scan, MRI, or x-ray) OR ≥ 10 mm by spiral CT scan&#xD;
&#xD;
               -  Must show clear evidence of disease progression within the lesion if the only&#xD;
                  site of measurable disease is within a previously irradiated volume&#xD;
&#xD;
          -  Standard curative or palliative measures do not exist OR are no longer effective&#xD;
&#xD;
          -  No history of or known brain metastases&#xD;
&#xD;
          -  Performance status - ECOG 0-1&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  Fasting cholesterol ≤ 350 mg/dL*&#xD;
&#xD;
          -  Triglycerides ≤ 400 mg/dL*&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile female patients must use effective contraception for ≥ 1 month before, during,&#xD;
             and for ≥ 3 months after completion of study treatment (during and for ≥ 3 months&#xD;
             after completion of study treatment for male patients)&#xD;
&#xD;
          -  No history of allergic reaction attributed to compounds of similar chemical or&#xD;
             biological composition to study drugs&#xD;
&#xD;
          -  No ongoing or active bacterial or viral infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No dementia or altered mental status that would preclude giving informed consent&#xD;
&#xD;
          -  No other uncontrolled illnesses&#xD;
&#xD;
          -  More than 3 weeks since prior immunotherapy&#xD;
&#xD;
          -  Prior biological therapy (e.g., interferon or interleukin 2, vaccine, antibody-based&#xD;
             and tyrosine kinase inhibitors) allowed&#xD;
&#xD;
          -  No concurrent prophylactic hematopoietic colony-stimulating factors except for epoetin&#xD;
             alfa&#xD;
&#xD;
          -  No prior cytotoxic chemotherapy&#xD;
&#xD;
          -  No prior bryostatin 1, temsirolimus, everolimus, or AP23573 for this malignancy&#xD;
&#xD;
          -  More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)&#xD;
&#xD;
          -  No concurrent steroids except for topical or inhaled use&#xD;
&#xD;
          -  No other concurrent experimental agents&#xD;
&#xD;
          -  No prior radiotherapy to &gt; 25% of bone marrow&#xD;
&#xD;
          -  More than 3 weeks since prior radiotherapy&#xD;
&#xD;
          -  More than 3 weeks since prior major surgery, including nephrectomy&#xD;
&#xD;
               -  Minor surgical procedures allowed&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  More than 3 weeks since prior other anticancer investigational agents&#xD;
&#xD;
          -  Concurrent CYP3A4 inducers or inhibitors allowed provided patient has been on a stable&#xD;
             dose for ≥ 1 week before study entry&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent antineoplastic agents or therapies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Hudes</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>June 2, 2005</study_first_submitted>
  <study_first_submitted_qc>June 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2005</study_first_posted>
  <last_update_submitted>May 1, 2013</last_update_submitted>
  <last_update_submitted_qc>May 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Bryostatin 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

